Found: 17
Select item for more details and to access through your institution.
PGV-1 Causes Disarrangement of Spindle Microtubule Organization Resulting in Aberrant Mitosis in HLF and HuH6 Cells Associated with Altered MYCN Status.
- Published in:
- Advanced Pharmaceutical Bulletin, 2024, v. 14, n. 3, p. 665, doi. 10.34172/apb.2024.058
- By:
- Publication type:
- Article
Preparation and Cytotoxic Evaluation of PGV-1 Derivative, CCA-1.1, as a New Curcumin Analog with Improved-Physicochemical and Pharmacological Properties.
- Published in:
- Advanced Pharmaceutical Bulletin, 2022, v. 12, n. 3, p. 603, doi. 10.34172/apb.2022.063
- By:
- Publication type:
- Article
CEP55 Inhibitor: Extensive Computational Approach Defining a New Target of Cell Cycle Machinery Agent.
- Published in:
- Advanced Pharmaceutical Bulletin, 2022, v. 12, n. 1, p. 191, doi. 10.34172/apb.2022.021
- By:
- Publication type:
- Article
Cell Cycle Modulation of CHO-K1 Cells Under Genistein Treatment Correlates with Cells Senescence, Apoptosis and ROS Level but in a Dose-Dependent Manner.
- Published in:
- Advanced Pharmaceutical Bulletin, 2019, v. 9, n. 3, p. 453, doi. 10.15171/apb.2019.054
- By:
- Publication type:
- Article
Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation.
- Published in:
- Advanced Pharmaceutical Bulletin, 2019, v. 9, n. 3, p. 445, doi. 10.15171/apb.2019.053
- By:
- Publication type:
- Article
Functional network analysis reveals potential repurposing of β-blocker atenolol for pancreatic cancer therapy.
- Published in:
- DARU: Journal of Pharmaceutical Sciences, 2020, v. 28, p. 685, doi. 10.1007/s40199-020-00375-4
- By:
- Publication type:
- Article
Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-18348-9
- By:
- Publication type:
- Article
Bioinformatic and Molecular Interaction Studies Uncover That CCA-1.1 and PGV-1 Differentially Target Mitotic Regulatory Protein and Have a Synergistic Effect against Leukemia Cells.
- Published in:
- Indonesian Journal of Pharmacy / Majalah Farmasi Indonesia, 2022, v. 33, n. 2, p. 225
- By:
- Publication type:
- Article
SYNTHESIS AND CYTOTOXIC ACTIVITY OF 2,5-BIS(4-BORONIC ACID)BENZYLIDINE CYCLOPENTANONE ON HER2 OVEREXPRESSED-CANCER CELLS.
- Published in:
- Indonesian Journal of Pharmacy / Majalah Farmasi Indonesia, 2017, v. 28, n. 2, p. 74, doi. 10.14499/indonesianjpharm28iss2pp74
- By:
- Publication type:
- Article
Comprehensive bioinformatics study reveals targets and molecular mechanism of hesperetin in overcoming breast cancer chemoresistance.
- Published in:
- Molecular Diversity, 2020, v. 24, n. 4, p. 933, doi. 10.1007/s11030-019-10003-2
- By:
- Publication type:
- Article
Supplementation with extract of pumpkin seeds exerts estrogenic effects upon the uterine, serum lipids, mammary glands, and bone density in ovariectomized rats.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The anti-migratory activity of a new curcumin analog, CCA-1.1, against T47D breast cancer cells.
- Published in:
- International Journal of Pharmaceutical Research (09752366), 2021, v. 13, n. 1, p. 2877, doi. 10.31838/ijpr/2021.13.01.421
- By:
- Publication type:
- Article
A new curcumin analog, CCA-1.1, induces cell cycle arrest and senescence toward ER-positive breast cancer cells.
- Published in:
- International Journal of Pharmaceutical Research (09752366), 2021, v. 13, n. 1, p. 1, doi. 10.31838/ijpr/2021.13.01.002
- By:
- Publication type:
- Article
Reactive oxygen species and senescence modulatory effects of rice bran extract on 4T1 and NIH-3T3 cells co-treatment with doxorubicin.
- Published in:
- Asian Pacific Journal of Tropical Biomedicine, 2021, v. 11, n. 4, p. 174, doi. 10.4103/2221-1691.310204
- By:
- Publication type:
- Article
Cellular uptake evaluation of pentagamaboronon-0 (PGB-0) for boron neutron capture therapy (BNCT) against breast cancer cells.
- Published in:
- Investigational New Drugs, 2019, v. 37, n. 6, p. 1292, doi. 10.1007/s10637-019-00765-9
- By:
- Publication type:
- Article
Synthesis and cytotoxicity of the boron carrier pentagamaboronon-0-ol for boron neutron capture therapy against breast cancer.
- Published in:
- Journal of Advanced Pharmaceutical Technology & Research, 2022, v. 13, n. 1, p. 70, doi. 10.4103/japtr.japtr_220_21
- By:
- Publication type:
- Article
Preparation of pentagamaboronon-0 and its fructose and sorbitol complexes as boron carrier for boron neutron capture therapy (BNCT) application.
- Published in:
- Research in Pharmaceutical Sciences, 2019, v. 14, n. 4, p. 286, doi. 10.4103/1735-5362.263552
- By:
- Publication type:
- Article